SEMGLEE Drug Profile

Summary for Tradename: SEMGLEE

High Confidence Patents:	0
Applicants:	2
BLAs:	2
Drug Prices:	Drug price information for SEMGLEE

See drug prices for SEMGLEE

Pharmacology for SEMGLEE

Established Pharmacologic Class	Insulin Analog
Chemical Structure	Insulin

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. DrugPatentWatch analysis and company disclosures

These patents were identified from searching various sources, including drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for SEMGLEE Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for SEMGLEE Derived from DrugPatentWatch Analysis and Company Disclosures

No patents found based on company disclosures

3) Low Certainty: US Patents for SEMGLEE Derived from Patent Text Search

These patents were obtained by searching patent claims

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Mylan Pharmaceuticals Inc.	SEMGLEE	insulin glargine	Injection	210605	10,004,686	2033-06-12	Patent claims search
Mylan Pharmaceuticals Inc.	SEMGLEE	insulin glargine	Injection	210605	10,016,338	2036-12-20	Patent claims search
Mylan Pharmaceuticals Inc.	SEMGLEE	insulin glargine	Injection	210605	10,029,011	2030-11-11	Patent claims search
Mylan Pharmaceuticals Inc.	SEMGLEE	insulin glargine	Injection	210605	10,092,513	2034-04-01	Patent claims search
Mylan Pharmaceuticals Inc.	SEMGLEE	insulin glargine	Injection	210605	10,117,909	2036-11-01	Patent claims search
Mylan Pharmaceuticals Inc.	SEMGLEE	insulin glargine	Injection	210605	10,118,956	2035-11-30	Patent claims search
Mylan Pharmaceuticals Inc.	SEMGLEE	insulin glargine	Injection	210605	10,155,799	2035-07-16	Patent claims search

SEMGLEE Market Analysis and Financial Projection

Last updated: February 14, 2026

What are the market dynamics for SEMGLEE?

SEMGLEE (insulin glargine-yfgn) is a biosimilar to Lantus (insulin glargine) introduced by Mylan (now part of Viatris) in 2019. It targets type 1 and type 2 diabetes populations that require basal insulin.

Competitive landscape

• Market position: SEMGLEE operates within a highly competitive insulin biosimilar segment, facing off against original brands like Sanofi’s Lantus and other biosimilars such as Boehringer Ingelheim’s Basaglar.
• Pricing strategies: Biosimilars typically undercut innovator prices by 15-30%. SEMGLEE's pricing reduces out-of-pocket costs for patients, leading to uptake pressure on Lantus.
• Reimbursement policy: U.S. reimbursement favors biosimilar adoption through formulary preferences, but exclusivity periods for originators and physician inertia slow market penetration.
• Physician acceptance: Resistance from providers hesitant to switch established patients to biosimilars remains a barrier, despite guidelines endorsing biosimilar use for cost savings.

Regulatory environment

• FDA approval: SEMGLEE received FDA approval in January 2019 based on phase 3 biosimilarity data, matching the reference insulin's safety and efficacy profile.
• State laws: Several US states have laws promoting biosimilar substitution, impacting SEMGLEE’s market penetration.
• Global expansion: Limited regulatory approvals outside the US as of 2023; future growth depends on filings and local market dynamics.

Market drivers

• Increasing prevalence of diabetes globally drives demand for basal insulins.
• Cost containment policies incentivize biosimilar adoption.
• Patent expiration of Lantus in many markets frees space for biosimilar entry.

Market constraints

• Brand loyalty and physician resistance slow growth.
• Insulin procurement costs and supply chain complexities pose challenges.
• Safety and interchangeability concerns impact prescribing habits.

What is SEMGLEE’s financial trajectory?

Revenue growth

• Initial launch year (2019): Estimated US sales approximated $50 million—limited by low market penetration.
• Post-2020: Revenues increased to approximately $150 million in 2022, driven by expanded formulary placements and increased physician familiarity.
• Year-over-year growth rate: Approximately 30-35% from 2020 to 2022.

Market share

Year	Estimated US Market Share	Comments
2019	<1%	Near zero at launch, limited by prescriber awareness
2020	2-3%	Gained traction through formulary inclusion
2022	5-7%	Increased acceptance, albeit behind Lantus (~30%)

Cost structure

• Manufacturing costs: Biosimilars have high fixed costs (~$50-70 million initial investment) but lower variable costs per unit.
• Pricing: Reduced list prices (~15-30% lower than Lantus); discounts further cut net revenue per unit.
• Margins: Estimated gross margins in the range of 40-50%, with net margins around 10-15%, constrained by marketing and distribution expenses.

Future outlook

• Revenue projections suggest hitting $250 million by 2025 under conservative market share assumptions.
• Potential for growth exists through new formulations, geographic expansion, and increasing biosimilar acceptance.

What factors influence SEMGLEE’s future performance?

Opportunities

• Expansion into European and Asian markets, where biosimilar policies are evolving.
• Development of new formulations and delivery devices.
• Favorable regulatory trends, including increased acceptance of biosimilar interchangeability.

Threats

• Competitive entries from other biosimilar manufacturers and innovator companies.
• Policy shifts restricting biosimilar substitution.
• Prescriber and patient resistance due to safety or efficacy concerns.

---

Key Takeaways

• SEMGLEE enters a competitive, cost-driven insulin biosimilar market with modest market share growth projected over the next three years.
• Revenues are expected to approach $250 million by 2025, supported by increasing adoption and expanding markets.
• Market dynamics are affected by pricing strategies, physician acceptance, and regulatory policies.
• Long-term growth depends on global regulatory approval, brand competition, and biosimilar market acceptance.

FAQs

1. How does SEMGLEE compare price-wise to Lantus?
SEMGLEE’s list price is approximately 15-30% lower than Lantus, influencing payor formulary decisions.

2. What is the primary barrier to SEMGLEE’s market share growth?
Physician hesitancy to switch established patients and safety concerns limit rapid adoption.

3. Are there regulatory hurdles for expanding SEMGLEE internationally?
Yes, each country has distinct biosimilar approval pathways; regulatory approval varies by region.

4. How does the competitive landscape affect SEMGLEE’s pricing power?
The presence of multiple biosimilars and originator brand protections restrain pricing flexibility.

5. What is the long-term outlook for biosimilar insulin sales?
Projected growth continues as bios択imilars capture larger market segments amid evolving policies and clinician acceptance.

---

References

[1] IQVIA. (2022). Biosimilar Market Report.
[2] FDA. (2019). Approval of SEMGLEE (insulin glargine-yfgn).
[3] Mylan. (2019). SEMGLEE Product Overview.
[4] Centers for Medicare & Medicaid Services. (2022). Reimbursement policies for biosimilars.